



MEETING SCHEDULE-AT-A-GLANCE

WEDNESDAY, FEBRUARY 21, 2007

7:00 a.m.-7:30 p.m.
Registration
Salon C Foyer

8:00 a.m.-12:00 noon
Global eHealth Innovation Through Tobacco Control: Lessons Learned from the Web-Assisted Tobacco Interventions (WATI) Initiative
Presented by the Web-Assisted Tobacco Interventions (WATI) Initiative
Meeting Room 408

9:00 a.m.-5:00 p.m.
Networking for Global Tobacco Reduction: The Role of SRNT
Presented by SRNT Global Network Committee
Salon F

10:00 a.m.-5:00 p.m.
Increasing Access to Effective Treatments: The Case for More Flexible Regulatory Policy
Presented by SRNT Policy Committee
Meeting Room 400

1:00 p.m.-5:00 p.m.
2007 Addressing Tobacco in Healthcare National Forum: Innovations in e-Health and e-Technology for Health Services Research
Presented by The Addressing Tobacco in Healthcare Research Network
Meeting Room 408

4:00 p.m.-9:00 p.m.
Cyber Café
Meeting Room 602

5:30 p.m.-7:00 p.m.
Welcome and Opening Remarks Awards Ceremony
Ellen Gritz, Ph.D., SRNT President
Neal Benowitz, Ph.D., SRNT Awards Committee Chair
Salon C

2007 Ove Ferno Award Address: Sharon Hall, Ph.D.
"Tobacco Dependence as a Chronic Relapsing Disorder: Co-morbidities and Complexities"

7:00 p.m.-8:30 p.m.
Welcome Reception/Exhibits Open
Salon H

THURSDAY, FEBRUARY 22, 2007

7:00 a.m.-9:00 p.m.
Cyber Café
Meeting Room 602

7:30 a.m.-5:00 p.m.
Registration
Salon C Foyer

8:30 a.m.-9:30 a.m.
Keynote Speaker: Jean-Pierre Changeux, Ph.D.
"Brain Nicotinic Receptors: From Molecular Biology to Cognition and Addiction"
Salon C

9:30 a.m.-10:00 a.m.
Refreshment Break
Salon J/K Foyer

10:00 a.m.-11:30 a.m.
Paper Session 1
Reward and Reinforcement
Salon F

10:00 a.m.-11:30 a.m.
Paper Session 2
Psychiatric Comorbidity
Salon G

10:00 a.m.-11:30 a.m.
Paper Session 3
Weight
Meeting Room 400

10:00 a.m.-11:30 a.m.
Paper Session 4
PREPS and Harm Reduction
Salon C

11:00 a.m.-7:00 p.m.
Exhibit Hall Open
Salon H

11:30 a.m.-1:30 p.m.
Poster Session I
Lunch
Boxed Lunches Served in Salon H-Exhibit Hall
(Exchange Your Lunch Ticket for a Boxed Lunch)

1:30 p.m.-3:00 p.m.
Symposium 1
A Translational Approach to Understanding Gender, Adolescence, and Vulnerability to Nicotine Addiction
Salon C

1:30 p.m.-3:00 p.m.
Symposium 2
Health Disparities and Tobacco Use
Salon F

1:30 p.m.-3:00 p.m.
Symposium 3
Nicotine in Non-Neuronal Cells
Meeting Room 400

1:30 p.m.-3:00 p.m.
Symposium 4
What Role, if Any, Does Dopamine Play in Cigarette Smoking?
Salon G

3:00 p.m.-3:30 p.m.
Refreshment Break in the Exhibit Hall
Salon H

3:30 p.m.-4:30 p.m.
Clinical Theme Lecture: Kenneth A. Perkins, Ph.D.
"Sex Differences In Nicotine and Non-Nicotine Reinforcement and Reward: Implications for Smoking Cessation Treatment"
Salon C

4:30 p.m.-5:45 p.m.
New Investigators Award Lecture and Paper Session
Salon C

6:00 p.m.-7:00 p.m.
Optional Workshops

Workshop 1
Tobacco Companies are Racketeers: An Update on the Federal Tobacco Lawsuit
Salon F

Workshop 2
The National Youth Tobacco Surveys From 1999 to 2006 - The Data, Access to the Data and Ways to Use the Data to Address Youth Tobacco Use
Salon G

Workshop 3
Applying for and Obtaining a Job: Perspectives from Academia, Medical Centers and Industry
Salon C

7:00 p.m.-8:30 p.m.
Graduate Student Reception
Open to all Graduate Students (others by invitation only)
Cash Bar and Hors d'oeuvres
Meeting Room 408

FRIDAY, FEBRUARY 23, 2007

7:00 a.m.-9:00 p.m.
Cyber Café
Meeting Room 602

7:15 a.m.-8:15 a.m.
Breakfast with the Champions
Presented by the SRNT Training Committee
Pre-registration required
Meeting Room 410

8:00 a.m.-5:00 p.m.
Registration
Salon C Foyer

8:30 a.m.-10:00 a.m.
Paper Session 5
Craving
Salon F

8:30 a.m.-10:00 a.m.
Paper Session 6
Pregnancy/Post-Partum
Meeting Room 400

8:30 a.m.-10:00 a.m.
Paper Session 7
Youth Smoking and the Media
Salon G

8:30 a.m.-10:00 a.m.
Paper Session 8
Geographic, Socioeconomic, Racial and Ethnic Factors
Salon C

10:00 a.m.-10:30 a.m.
Refreshment Break
Salon J/K Foyer

10:30 a.m.-11:30 a.m.
Pre-Clinical Theme Lecture: Anthony R. Caggiula, Ph.D.
"What is the Role of Nicotine in Smoking? A Perspective from Animal Research"
Salon C

11:00 a.m.-5:00 p.m.
Exhibit Hall Open
Salon H

11:30 a.m.-1:30 p.m.
Poster Session II
Lunch
Boxed Lunches Served in Salon H
(Exchange Your Lunch Ticket for a Boxed Lunch)

1:30 p.m.-3:00 p.m.
Symposium 5
Factors that Impact Nicotine Bioavailability: Findings from the Transdisciplinary Tobacco Use Research Centers Program
Salon G

1:30 p.m.-3:00 p.m.
Symposium 6
Expansion of Non-Cigarette Tobacco Products: Current Research and Policy Implications
Salon F

1:30 p.m.-3:00 p.m.
Symposium 7
Using Social Marketing to Influence Tobacco Use Behavior: The Experience of the American Legacy Foundation
Meeting Room 400

1:30 p.m.-3:00 p.m.
Symposium 8
Addressing Comorbid Psychiatric Problems in the Treatment of Nicotine Dependence
Salon C

3:00 p.m.-3:30 p.m.
Refreshment Break
Salon H-Exhibit Hall

3:30 p.m.-4:30 p.m.
Epidemiology/Public Health Theme Lecture: Ronald Borland, Ph.D.
"Integrating Tobacco Industry and Tobacco Use Control: Tackling Harm and Dependence in a Culture of Consumption"
Salon C

4:30 p.m.-5:30 p.m.
Members' Meeting
Salon C

SATURDAY, FEBRUARY 24, 2007

7:00 a.m.-3:00 p.m.
Cyber Café
Meeting Room 602

7:30 a.m.-2:30 p.m.
Registration
Salon C Foyer

SCHEDULE-AT-A-GLANCE • PROGRAM



8:00 a.m.-9:30 a.m.
Symposium 9
 Human Allelic Variation that Contributes to Nicotine Dependence and Success in Smoking Cessation
 Meeting Room 400

8:00 a.m.-9:30 a.m.
Symposium 10
 Molecules to Behavior: The Influence of Gender and Hormones on Responses to Nicotine and Smoking Cessation
 Salon G

8:00 a.m.-9:30 a.m.
Symposium 11
 Cue-Provoked Craving: Observations, Mechanisms, and Clinical Implications
 Salon C

8:00 a.m.-9:30 a.m.
Symposium 12
 Parent Smoking, Parenting, and Adolescent Smoking: Moderators, Mediators, and Reciprocal Influence
 Salon F

9:30 a.m.-10:00 a.m.
Refreshment Break
 Salon J/K Foyer

10:00 a.m.-11:30 a.m.
Paper Session 9
 Biological Variation
 Salon G

10:00 a.m.-11:30 a.m.
Paper Session 10
 Attention
 Meeting Room 400

10:00 a.m.-11:30 a.m.
Paper Session 11
 New Medications
 Salon F

10:00 a.m.-11:30 a.m.
Paper Session 12
 Predictors of Change in Smoking
 Salon C

11:30 a.m.-1:30 p.m.
Poster Session 3
Rapid Response Posters
 Boxed Lunches
 Served in Salon H—Exhibit Hall
 (Exchange Your Lunch Ticket for a Boxed Lunch)

1:30 p.m.-2:00 p.m.
Closing Remarks
 Salon C

Program: Wednesday, February 21, 2007 through Saturday, February 24, 2007

WEDNESDAY, FEBRUARY 21, 2007

7:00 a.m.-7:30 p.m...... Salon C Foyer
Registration

8:00 a.m.-12:00 noon Meeting Room 408
Global eHealth Innovation Through Tobacco Control: Lessons Learned from the Web-Assisted Tobacco Interventions (WATI) Initiative

The Web-Assisted Tobacco Interventions (WATI) Initiative, directed by Drs. Peter Selby and Scott McIntosh, present this pre-conference on the use of technology to send health promotion messages and to help smokers quit and stay quit. This growing area of research and practice has been called Web-Assisted Tobacco Interventions. The problem is finding ways to create shared knowledge frameworks when a field is new and those creating the knowledge are physically located all around the globe. This workshop will provide a venue for practitioners, researchers, policy makers and funders to network and exchange knowledge about WATI initiatives and to build capacity for technology-enabled tobacco control. By bringing together experts from different countries, disciplines and interests related to WATI, the workshop has the potential to create a lasting network of knowledge exchange and collaboration that can further advance tobacco control and eHealth capacity.

9:00 a.m.-5:00 p.m. Salon F
Networking for Global Tobacco Reduction: The Role of SRNT

Presented by SRNT Global Network Committee.

This pre-conference workshop will feature the opening session with Yumiko Mochizuki-Kobayashi, Director, Tobacco Free Initiative, World Health Organization; Prakash Gupta, President 14th World Conference on Tobacco OR Health, and Laurent Huber, Framework Convention alliance. Additional sessions will include “The Bloomberg Initiative: Advancing Science, Advancing Tobacco Reduction in Developing Countries”; “Perspectives on the Role of SRNT in Advancing Science and Facilitating Networking”; “Developing Country Perspectives and Next Steps,” and open discussion.

10:00 a.m.-5:00 p.m...... Meeting Room 400
Increasing Access to Effective Treatments: The Case for More Flexible Regulatory Policy

This pre-conference workshop, funded by the U.S. National Institute on Drug Abuse, the U.S. National Cancer Institute, the Robert Wood Johnson Foundation, and the Roswell Park Cancer Institute TTURC, will focus on identifying barriers to the use of evidence-based treatment along with evidence-based solutions to overcome these barriers. The workshop will also include presentations on misperceptions of current treatments, consumer attitudes toward treatment, discussion of policy solutions developed by several countries, the preliminary results of a U.S.-based literature review on barriers to treatment, and a discussion of non-evidence based treatments.

1:00 p.m.-5:00 p.m...... Meeting Room 408
2007 Addressing Tobacco in Healthcare National Forum: Innovations in e-Health and e-Technology for Health Services Research

Presented by The Addressing Tobacco in Healthcare Research Network.

The Addressing Tobacco in Healthcare Research Network, directed by Dr. Sue Curry and Dr. Michael Fiore and funded by The Robert Wood Johnson Foundation presents this pre-conference on innovations in e-health and e-technology for health services research.

4:00 p.m.-9:00 p.m...... Meeting Room 602
Cyber Café

5:30 p.m.-7:00 p.m. Salon C
Welcome and Opening Remarks; Awards Ceremony & Ove Ferno Award Address

Ellen Gritz, Ph.D., SRNT President

Award Presentations

Session Chair: Neal Benowitz, Ph.D., SRNT Awards Committee Chair



WEDNESDAY, FEBRUARY 21 - THURSDAY, FEBRUARY 22, 2007

2007 John Slade Award Winner:

C. Tracy Orleans, Ph.D.

Introduction by Sue Curry, Ph.D. and Jessie Gruman, Ph.D.

2007 Jarvik-Russell Investigator Award Winner:

Judith Prochaska, Ph.D., M.P.H.

Introduction by Phillip Gardiner, Ph.D.

2007 Ove Ferno Award Winner:

Sharon M. Hall, Ph.D.

2007 Ove Ferno Award Address:

"Tobacco Dependence as a Chronic Relapsing Disorder:
Co-morbidities and Complexities"

Introduction by Maxine L. Stitzer, Ph.D.

7:00 p.m.-8:30 p.m. **Salon H**

Welcome Reception/Exhibits Open

Cash Bar, Music and Light Hors d'Oeuvres

THURSDAY, FEBRUARY 22, 2007

7:00 a.m.-9:00 p.m. **Meeting Room 602**

Cyber Café

7:30 a.m.-5:00 p.m. **Salon C Foyer**

Registration

8:30 a.m. 9:30 a.m. **Salon C**

Keynote Address: Jean-Pierre Changeux, Ph.D.

"Brain Nicotinic Receptors: From Molecular Biology to
Cognition and Addiction"

Introduction by David Balfour, Ph.D.

9:30 a.m.-10:00 a.m. **Salon J/K Foyer**

Refreshment Break

PAPER SESSIONS 1-4

10:00 a.m.-11:30 a.m. **Salon F**

Paper Session 1: Reward and Reinforcement

Session Chairs: Edward D. Levin, Ph.D. and Sherry McKee, Ph.D.

10:00 a.m.

PA1-1

**SLOWER BRAIN UPTAKE OF INHALED NICOTINE IN
DEPENDENT CIGARETTE SMOKERS THAN IN NON-
DEPENDENT SMOKERS**

Jed E. Rose, Sudha Garg, Stephen J. Lokitz, Timothy G.
Turkington, Richard C. Minton, Holly C. Smith, Joseph E.
Herskovic, Frederique M. Behm, Sarah Wildrick, Pradeep
K. Garg, Duke Center for Nicotine and Smoking
Cessation Research, Durham, NC*

10:15 a.m.

PA1-2

**EFFECT OF ALCOHOL ON REACTIVITY TO TOBACCO IN
HEAVY DRINKING YOUNG ADULT NON-DAILY SMOKERS**

Sherry A. McKee, Ph.D., Patricia Allen, B.S., Sabrina
Pizzola, B.A., Naralys Estevez, B.S., Yale University
School of Medicine*

10:30 a.m.

PA1-3

**CREB1 SNPS AND HAPLOTYPES MODERATE
RESPONSE TO NALTREXONE**

**Ray R.^{1,2}, Jepson C.², Wileyto P.², Patterson F.²,
Strasser A.², Rukstalis M.², Perkins K.³, O'Malley S.⁴,
Berrettini W.², Lerman C.² ¹Department of Pharmacology,
University of Pennsylvania, Philadelphia, PA 19104;
²Department of Psychiatry, University of Pennsylvania,
Philadelphia, PA 19104; ³Department of Psychiatry,
University of Pittsburgh School of Medicine, Pittsburgh,
PA 15213; ⁴Department of Psychiatry, Yale University
School of Medicine, New Haven, CT 06519*

10:45 a.m.

PA1-4

**RESPONSE COST INFLUENCES NICOTINE SELF-
ADMINISTRATION DIFFERENTIALLY IN ADOLESCENT
AND ADULT RATS**

Megan J. Shram, M.Sc.,^{1,2}, Douglas Funk, Ph.D.²,
Zhaoxia Li,² A.D. Lê, Ph.D.^{1,2} ¹Department of
Pharmacology, University of Toronto; ²Department of
Neuroscience, Centre for Addiction and Mental Health*

11:00 a.m.

PA1-5

**KETANSERIN, A SEROTONIN TYPE-2 RECEPTOR
ANTAGONIST, DECREASES NICOTINE SELF-
ADMINISTRATION IN RATS**

Edward D. Levin, Ph.D., Susan Lawrence, B.S., Ann
Petro, M.S., Kofi Horton, B.S., Paul Williams, B.A. and
Amir H. Rezvani, Ph.D., Department of Psychiatry and
Behavioral Sciences, Duke University Medical Center*

11:15 a.m.

PA1-6

**INFLUENCE OF DRUG ASSOCIATED STIMULI ON INTRA-
VENOUS NICOTINE SELF-ADMINISTRATION BEHAVIOR:
INSIGHTS FROM NON-HUMAN PRIMATES STUDIES**

Bernard Le Foll, Steven R. Goldberg² ¹Translational
Addiction Research Laboratory, Centre for Addiction and
Mental Health, 33 Russell Street, Toronto, ON M5S 2S1;
²Preclinical Pharmacology Section, Behavioral
Neuroscience Research Branch, Intramural Research
Program, National Institute on Drug Abuse, National
Institutes of Health, Department of Health and Human
Services, Baltimore, Maryland, USA*



10:00 a.m.-11:30 a.m. Salon G
Paper Session 2: Psychiatric Comorbidity

Session Chairs: Brian Hitsman, Ph.D. and Jill M. Williams, M.D.

10:00 a.m.

PA2-1

CORRELATION OF PREPULSE INHIBITION WITH WISCONSIN CARD SORTING TEST PERFORMANCE IN SCHIZOPHRENIA AND CONTROLS: EFFECTS OF SMOKING STATUS

Kristi Sacco, Psy.D.¹, Tony P. George, M.D.^{1,2} ¹Program for Research in Smokers with Mental Illness, Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519; ²Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5S 2S1

10:15 a.m.

PA2-2

RANDOMIZED CONTROLLED TRIAL OF A SMOKING CESSATION INTERVENTION AMONG PEOPLE WITH A PSYCHOTIC DISORDER: 3-YEAR FOLLOW-UP

Amanda Baker, Ph.D.^{1,2}, Robyn Richmond, Ph.D.³, Frances Kay-Lambkin, Ph.D.², Terry J. Lewin, B. Com. (Psych.) Hons^{1,2}, Vaughan J. Carr, M.D., F.R.A.N.Z.C.P.^{1,2} ¹Centre for Mental Health Studies, University of Newcastle and Hunter New England Mental Health, University Drive, Callaghan, NSW 2308, Australia; ²Neuroscience Institute of Schizophrenia and Allied Disorders (NISAD), Darlinghurst, Sydney, NSW 2010, Australia; ³School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW 2052, Australia*

10:30 a.m.

PA2-3

NO ADVANTAGE FOR HIGH DOSE COMPARED TO REGULAR DOSE NICOTINE PATCH ON SHORT-TERM ABSTINENCE RATES IN SCHIZOPHRENIA

Jill M. Williams, M.D.^{1,2}, Kunal K. Gandhi, M.B.B.S, M.P.H.^{1,2}, Jonathan Foulds, Ph.D.^{1,2}, Michael Steinberg, M.D., M.P.H.^{1,2}, Shou-en Lu, Ph.D.², Fatima Masumova³, Teo Carlo-Straun, B.S.¹, and Douglas Ziedonis, M.D., M.P.H.^{1,2} ¹UMDNJ-Robert Wood Johnson Medical School. ²UMDNJ-School of Public Health; ³Rutgers University

10:45 a.m.

PA2-4

SUSTAINED-RELEASE BUPROPION COMBINED WITH TRANSDERMAL NICOTINE PATCH FOR SMOKING CESSATION IN SCHIZOPHRENIA: RESULTS OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL.

Andrea H. Weinberger, Jennifer C. Vessicchio¹, Kristi A. Sacco¹, Tony P. George^{1,2} ¹Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT USA 06519; ²Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto Faculty of Medicine, Toronto, Canada, M5S 2S1*

11:00 a.m.

PA2-5

COMORBIDITY OF NICOTINE DEPENDENCE AND PSYCHIATRIC DISORDERS IN A COMMUNITY ADOLESCENT SAMPLE

Pamela C. Griesler, Ph.D.^{1,2}, Mei-Chen, Hu, Ph.D.³, Christine Schaffran, M.A.², Denise B. Kandel, Ph.D. ^{1,2,3} ¹Department of Psychiatry, Columbia University; ²New York State Psychiatric Institute; ³Mailman School of Public Health, Columbia University*

11:15 a.m.

PA2-6

EFFECTS OF SMOKING INITIATION AND PROGRESSION ON CHANGE IN DEPRESSION SYMPTOM SCORE IN MALE AND FEMALE ADOLESCENTS: EVIDENCE FROM THE ADDHEALTH STUDY

Marcus R. Munafo, Ph.D., University of Bristol; Brian Hitsman, Ph.D., Richard Rende, Ph.D., Raymond Niaura, Ph.D., Brown University*

10:00 a.m.-11:30 a.m. Meeting Room 400
Paper Session 3: Weight

Session Chairs: Michelle D. Levine, Ph.D. and Steven C. Ames, Ph.D.

10:00 a.m.

PA3-1

IMPACT OF SMOKERS' PRIOR QUITTING HISTORY ON CURRENT CESSATION ATTEMPTS

Virginia C. Reichert, N.P., Patricia Folan, R.N., Daniel Jacobsen, R.N., Diane Bartscherer, R.N., Christine Fardellone, R.N., North Shore-LIJ Health System, Center for Tobacco Control; Arunabh Talwar, M.D., Division of Pulmonary, Critical Care and Sleep Medicine, North Shore University Hospital; Nina Kohn, M.B.A., M.A., Biostatistics Unit, North Shore-LIJ Health System; Christine Metz, Ph.D., Feinstein Institute for Medical Research, North Shore-LIJ Health System*

10:15 a.m.

PA3-2

EFFECTS OF A BODY IMAGE MANIPULATION ON SMOKING MOTIVATION IN COLLEGE WOMEN

Elena Lopez, M.A., Erika Litvin, B.A., Courtney Collins, B.A., Katie James, David Drobos, Ph.D., Kevin Thompson, Ph.D., Thomas Brandon, Ph.D., University of South Florida, Tampa, FL*

10:30 a.m.

PA3-3

BUPROPION AND COGNITIVE BEHAVIORAL TREATMENT FOR WEIGHT CONCERNS IMPROVES SMOKING CESSATION OUTCOME AMONG WEIGHT CONCERNED WOMEN

Michele D. Levine, Kenneth A. Perkins, Jennifer Slane, Donielle M. Neal, Marsha D. Marcus, University of Pittsburgh, Pittsburgh, PA*



10:45 a.m.

PA3-4

NALTREXONE AUGMENTATION OF BUPROPION TO STOP SMOKING WITH LESS WEIGHT GAIN

Benjamin Toll, Ph.D., Vanessa Leary, B.A., Ran Wu, M.S., Peter Salovey, Ph.D., Boris Meandzija, M.D., Stephanie O'Malley, Ph.D., Yale University*

11:00 a.m.

PA3-5

BEHAVIORAL INTERVENTIONS TO CONTROL CESSATION-RELATED WEIGHT GAIN: WHAT DO WE KNOW? WHERE SHOULD WE GO?

Bonnie Spring, Ph.D., Northwestern University, Feinberg School of Medicine

11:15 a.m.

PA3-6

EXPRESSIVE WRITING AS A TREATMENT ADJUNCT TO REDUCE WEIGHT GAIN IN YOUNG ADULT SMOKERS UNDERGOING SMOKING CESSATION

Steven C. Ames, Ph.D., Gretchen E. Ames, Ph.D., Susanna R. Stevens, M.S., Christi A. Patten, Ph.D., Chudley E. Werch, Ph.D., Darrell R. Schroeder, M.S. Mayo Clinic, Jacksonville, FL and Rochester, MN*

10:00 a.m.-11:30 a.m. Salon C

Paper Session 4: PREPS and Harm Reduction

Session Chairs: Dorothy K. Hatsukami, Ph.D. and Andrew A. Strasser, Ph.D.

10:00 a.m.

PA4-1

CONSUMER AWARENESS AND ATTITUDES RELATED TO NEW POTENTIAL REDUCE-EXPOSURE TOBACCO PRODUCT BRANDS

Mark Parascandola, Ph.D., M.P.H., Erik Augustson, Ph.D., M.P.H., Ami Hurd, M.P.H., Stephen Marcus, Ph.D., National Cancer Institute*

10:15 a.m.

PA4-2

USE OF MULTIDIMENSIONAL SHORT TERM APPROACHES TO EVALUATE A NEW REDUCED EXPOSURE PRODUCT

Vaughan W. Rees, Ph.D., Geoffrey Ferris Wayne, M.A., & Gregory N. Connolly, D.M.D., M.P.H., Harvard School of Public Health*

10:30 a.m.

PA4-3

NICOTINE PHARMACOKINETICS AND SUBJECTIVE EFFECTS OF FIVE SMOKELESS TOBACCO PRODUCTS

Michael Kotlyar, Pharm.D., M. Irene Mendoza-Baumgart, M.D., Zhong-ze Li, M.S., Paul R. Pentel, M.D., Brianne C. Barnett, B.S., Rachel M. Feuer, B.A., Erin A. Smith, B.S., Dorothy K. Hatsukami, Ph.D., University of Minnesota*

10:45 a.m.

PA4-4

FALSE PERCEPTIONS, COMPENSATORY SMOKING, AND HARM EXPOSURE RELATED TO QUEST CIGARETTES

Andrew A. Strasser, Paul M. Sanborn, Kathy Z. Tang, Joseph N. Cappella, William Shadel, Caryn Lerman, University of Pennsylvania*

11:00 a.m.

PA4-5

SWITCHING TO LIGHT CIGARETTES AND SMOKING CESSATION: RESULTS OF THE 2003 TOBACCO USE SPECIAL CESSATION SUPPLEMENT TO THE CURRENT POPULATION SURVEY

Hilary Tindle, Saul Shiffman¹, Anne Hartman², James Bost¹ ¹University of Pittsburgh; ²National Cancer Institute*

11:15 a.m.

PA4-6

EPIDEMIOLOGICAL ASSOCIATION OF SNUFF USE WITH CHRONIC BRONCHITIS IN BLACK SOUTH AFRICAN WOMEN

Olalekan A. Ayo-Yusuf, B.D.S., M.Sc., M.P.H., University of Pretoria; Priscilla S. Reddy, Ph.D., Medical Research Council, South Africa; Bart H.W. van den Borne, Ph.D., Maastricht University, The Netherlands*

11:00 a.m.-7:00 p.m. Salon H Exhibit Hall Open

11:30 a.m.-1:30 p.m. Salon H – Exhibit Hall Poster Session I

Lunch

Boxed Lunches Served in Salon H – Exhibit Hall
(Exchange Your Lunch Ticket for a Boxed Lunch)

SYMPOSIUM SESSIONS I-4

1:30 p.m.-3:00 p.m. Salon C Symposium 1

A Translational Approach to Understanding Gender, Adolescence, and Vulnerability to Nicotine Addiction

Although it is known that teens are far more likely to become smokers than if they initiated smoking at an older age, adolescence as a unique developmental period has only come to the forefront of addiction research in recent years. In addition to age-related differences in responses to nicotine, there is mounting evidence that sex/gender is a critical factor that interacts with developmental vulnerability and that adolescent females are especially vulnerable to nicotine. The animal research may help explain what is seen in the humans, as well as some possible underlying factors, such as genetics or changes in neurobiology. For example, could changes in the relative compositions of nAChR populations underlie some of nicotine's effects on attention? Do sex differences in adolescence persist into adulthood? Each speaker's presentation will have the overarching goal of



explaining how their findings can be translated to what is seen in real-world populations. Dr. Edward Levin will discuss sex differences in the rate of nicotine self-administration in male versus female rats, and between adolescent vs. adult rats. Dr. Laura O'Dell will discuss developmental differences related to enhanced nicotine reward and lowered nicotine withdrawal in adolescent versus adult male rats. Dr. Cheryl Oncken will discuss clinical research examining the relationship between prenatal tobacco exposure, gender, and progression of nicotine dependence in the offspring. Dr. Eric Moolchan will discuss differential vulnerability as related to potential variations in nicotine metabolism, developmental trajectory or differences in quit attempts, as seen among dependent cessation-treatment seeking adolescents. This symposium seeks to combine basic animal research with human research in an effort to understand this enhanced vulnerability.

Presenters: Edward D. Levin, Ph.D., Duke University; Laura E. O'Dell, Ph.D., Scripps Research Institute; Eric Moolchan, M.D., National Institute on Drug Abuse; Cheryl Oncken, M.D., University of Connecticut; Cora Lee Wetherington, Ph.D., Allison Chausmer*, Ph.D., National Institute on Drug Abuse.*

1:30 p.m.-3:00 p.m. Salon F Symposium 2

Health Disparities and Tobacco Use

Health disparities are a critical public health problem and one of the two overarching goals of Healthy People 2010 is "To eliminate health disparities." Tobacco use is a major determinant of disparities. Recent national data indicate that 58% of the socioeconomic gradient in male mortality is attributable to tobacco and the Trans-HSS Cancer Health Disparities Progress Review Group called for the immediate implementation of evidence-based tobacco control strategies among the underserved. The goals of this symposium are to define tobacco-related disparities; highlight the profound gaps in our research knowledge; and present recent studies addressing tobacco use etiology and treatment among the underserved. Dr. Wetter will introduce the symposium, define tobacco-related disparities, and underscore the dearth of research among underserved populations. Dr. Mazas will present data from Adios al Fumar, a randomized clinical trial designed to increase the reach of the Spanish language smoking cessation counseling service of the National Cancer Institute's Cancer Information Service (CIS), and evaluate the efficacy of a culturally sensitive, proactive, telephone counseling program among Latinos. Adios increased calls over 45-fold, television was the most cost-effective method for reaching Latino smokers, and the counseling program was effective. Dr. Okuyemi will present data from four randomized controlled trials of pharmacotherapies among African American smokers (patch, spray, gum, bupropion). The overall results show only modest effects for pharmacotherapy among African American smokers. Dr. Sargent will present data from 6,522 U.S. adolescents who were surveyed at 8- month intervals for 2 years. Although African American and Latino adolescents had similar rates of experimentation, they were much less likely to progress to later stages of smoking over the course of the study, even though they were more likely (African-Americans in particular) to exhibit profiles characteristic of greater risk for progression to regular smoking.

The results pose theoretical challenges for current models of smoking initiation. Dr. Ahluwalia will serve as discussant.

Presenters: David W. Wetter, Ph.D., Carlos A. Mazas, Ph.D., University of Texas M.D. Anderson Cancer Center; Kolawole S. Okuyemi, M.D., Jasjit Ahluwalia, M.D., University of Minnesota; and James Sargent, M.D., Dartmouth Medical School*

1:30 p.m.-3:00 p.m. Meeting Room 400 Symposium 3

Nicotine in Non-Neuronal Cells

Nicotine has been used for several decades with demonstrated safety and efficacy for smoking cessation in clinical trials. There have been no trials or epidemiologic studies examining the effect of long-term medicinal nicotine use. However, it is undoubtedly much safer than persistent smoking with its attendant delivery of innumerable carcinogens and toxins. Also, data particularly from Sweden, has suggested that long-term use of low nitrosamine snus, which still delivers sufficient nicotine to support addiction, has a better safety profile than smoking. However, even studies in Sweden examining smokeless tobacco finds risks for heart disease and pancreatic cancer. In the past several years, exciting emerging science has been describing the effect of nicotine on non-neuronal cells and its potential pivotal role in stimulating angiogenesis, cellular proliferation and inhibition of apoptosis. These mechanisms work through similar nicotinic acetylcholine receptors as those found in the central nervous system and its reward pathways. All of this information provides additional emphasis for the importance of smoking cessation and mechanistic reasons for different clinical effects of smoking. In addition, there should be prospective trials examining these effects in people who use either nicotine or proposed "harm reduction" products long-term. As scientists outside of the usual SRNT environments are performing this research, this symposium would bring intriguing new information.

*Presenters: Neal Benowitz, Ph.D., Phillip Dennis, John Cooke, M.D., Ph.D., Carolyn Dresler**

1:30 p.m.-3:00 p.m. Salon G Symposium 4

What Role, If Any, Does Dopamine Play in Cigarette Smoking?

Dopamine is widely thought to play an important role in nicotine dependence, but quite what this role may be is far from settled. The aim of this session is to highlight major points of agreement and disagreement in this debate. Arguably, the strongest evidence that nicotine's reinforcing effects are mediated by dopamine comes from intravenous self-administration studies in rats. The validity of this widely-used animal model will be questioned by Robert Sorge. In particular, he will show that, contrary to popular belief, ultra-rapid ("bolus") infusions of nicotine are not required, nor are they necessarily more reinforcing than slower infusions which more nearly model the kinetics of nicotine delivery in smokers. He will also discuss the critical role of sensory cues in supporting drug self-administration. Derek van der Kooy will present studies using conditioned place preference that support the novel and controversial notion that dopamine mediates aversive rather than rewarding effects of nicotine. Alain Dagher



will describe PET and fMRI imaging studies examining the effects of cigarette smoking and cigarette craving on the dopamine system. These studies aim to understand the neurological factors involved in addiction and relapse. Arthur Brody will report that smokers with genes associated with low resting dopamine tone have greater smoking-induced (phasic) dopamine release than those with alternate genotypes. He will also present PET imaging data suggesting that alpha4 beta2 nAChRs are saturated in the brains of cigarette smokers, and will propose a role for desensitized receptors in the motivation to smoke. Lastly, Paul Clarke (Discussant) will examine all the above - and more - with a critical eye.

Presenters: Robert E. Sorge, Ph.D., Paul B.S. Clarke, Ph.D., McGill University; Derek van der Kooy, Ph.D., University of Toronto; Alain Dagher, M.D., Montreal Neurological Institute; Arthur L. Brody M.D., University of California at Los Angeles*

**3:00 p.m.-3:30 p.m. Salon H – Exhibit Hall
Refreshment Break**

**3:30 p.m.-4:30 p.m. Salon C
Clinical Theme Lecture: Kenneth A. Perkins, Ph.D.
“Sex Differences in Nicotine and Non-Nicotine
Reinforcement and Reward: Implications for Smoking
Cessation Treatment”**

Introduction by Caryn Lerman, Ph.D.

**4:30 p.m.-5:45 p.m. Salon C
New Investigator Award Lecture and Paper Session**

*Session Chair: Bernard LeFoll, M.D., Ph.D.
Presenters: Joshua H. West, M.P.H., Ryan Vandrey, Ph.D.,
and Dawn Lawhon, Ph.D.
Judith Prochaska, Ph.D., M.P.H., SRNT 2007 Jarvik-Russell
Award Recipient*

**4:30 p.m.
PANI-1
ADOLESCENT RECEPTIVITY TO TOBACCO MARKETING
ACROSS RACE/ETHNIC GROUPS IN CALIFORNIA**

*Joshua H. West, M.P.H., San Diego State University/
University of California; Dennis R. Trinidad, Ph.D., M.P.H.,
University of California, San Diego; Romina Romero,
M.P.H.*, San Diego State University/University of
California, San Diego; John P. Pierce, Ph.D., University of
California, San Diego*

**4:45 p.m.
PANI-2
EFFECTS OF NICOTINE EXPOSURE FOLLOWING BRIEF
ABSTINENCE: AN EXAMINATION OF HUMAN DRUG
PRIMING EFFECTS**

Ryan Vandrey, Ph.D., Maxine L. Stitzer, Ph.D., Johns
Hopkins University; Eric C. Donny, Ph.D., University of
Pittsburgh*

**5:00 p.m.
PANI-3
ABSTINENCE-SPECIFIC SOCIAL SUPPORT FOR
SMOKING CESSATION: A LONGITUDINAL ANALYSIS**

Dawn Lawhon, Ph.D., Gary L. Humfleet, Ph.D., Sharon
M. Hall, Ph.D., Victor I. Reus, M.D., Ricardo F. Muñoz,
Ph.D., University of California, San Francisco Treatment*

**5:15 p.m.
PANI-4
BREAKING DOWN THE BARRIERS TO TREATING
TOBACCO AMONG INDIVIDUALS WITH MENTAL
ILLNESS**

This year’s recipient of the 2007 Jarvik-Russell Award (formerly the SRNT Young Investigator Award) is Dr. Judith Prochaska. Dr. Prochaska will deliver a 25-minute lecture on her emerging program of research. Dr. Prochaska’s award will be presented to her at the Opening Reception and Awards Ceremony, which will be held on Wednesday, February 21, from 5:30 p.m.-7:00 p.m.

Judith Prochaska, Ph.D., M.P.H., Department of
Psychiatry, University of California, San Francisco, CA*

**6:00 p.m.-7:00 p.m.
Optional Workshops**

**6:00 p.m.-7:00 p.m.
Salon F
Workshop 1: Tobacco Companies are Racketeers:
An Update on the Federal Tobacco Lawsuit**

*Moderator: Dr. Michele Bloch, National Cancer Institute
Presenters: Richard Daynard, J.D., Ph.D., Northeastern
University School of Law, D. Douglas Blanke, J.D., William
Mitchell College of Law, Matthew Barry, M.P.A., Campaign
for Tobacco Free Kids, and Mitch Zeller, J.D., Pinney
Associates*

In 1999, the U.S. Department of Justice filed a landmark lawsuit against the U.S. tobacco manufacturers; on August 17, 2006, U.S. District Judge Gladys Kessler decided the case for the government, convicting the tobacco manufacturers of racketeering. Judge Kessler’s powerfully worded decision explains in extraordinary detail how cigarette manufacturers “marketed and sold their lethal product with zeal, with deception, and with a single-minded focus on their financial success, and without regard for the human tragedy or social costs that success exacted.” This workshop will provide an overview of the case, review the Judge’s ruling and its importance to public health, and describe how the ruling can be used to enhance the adoption of evidence-based tobacco control and prevention measures.



6:00 p.m.-7:00 p.m.

Salon G

Workshop 2: The National Youth Tobacco Surveys From 1999 to 2006 - The Data, Access to the Data and Ways to Use the Data to Address Youth Tobacco Use

Moderator: Ann Malacher, CDC Office on Smoking and Health

Presenters: Jennifer Duke, American Legacy Foundation; Paul Mowery, Biostatistics Inc.; Linda Pederson, CDC Office on Smoking and Health

The purpose of this workshop is to provide participants with an overview of the National Youth Tobacco Survey (NYTS), to briefly describe the methods for data collection and the content of the instrument, and to demonstrate how the survey can be used for research and surveillance. The NYTS provides national data about the tobacco-related beliefs, attitudes and behaviors of middle and high school youth, and the pro- and anti-tobacco influences to which they are exposed. These data are used to estimate trends in youth tobacco use, attitudes, and beliefs. The data for 1999, 2000, 2002 and 2004 will be available on the Office of Smoking and Health (CDC) website for use by researchers.

6:00 p.m.-7:00 p.m.

Salon C

Workshop 3: Applying for and Obtaining a Job: Perspectives from Academia, Medical Centers and Industry

Moderator: Dennis McChargue, Ph.D.

Presenters: Bill Shadel, Ph.D., RAND Corporation; Lee Cohen, Ph.D., Texas Tech University; Allison Chausmer, Ph.D., NIH/NIDA; and Bonnie Spring, Ph.D., Northwestern University and Feinberg School of Medicine

The Society for Research in Nicotine and Tobacco Training Committee is sponsoring a panel discussion focused on differing career paths of junior colleagues. The panel is comprised of respected researchers/faculty from academia, medical centers, industry, and NIH. Panelists will discuss a variety topics related to the types of jobs for junior colleagues, needed experiences, successful profiles; and common obstacles/mistakes made by junior colleagues.

7:00 p.m.-8:30 p.m. Meeting Room 408 Graduate Student Reception

Open to Graduate Students (others by invitation only)

Cash Bar and Light Hors d'Oeuvres

FRIDAY, FEBRUARY 23, 2007

7:00 a.m.-9:00 p.m. Meeting Room 602 Cyber Café

7:15 a.m.-8:15 a.m. Meeting Room 410 Breakfast with the Champions

Pre-registration required

Presented by the SRNT Training Committee

8:00 a.m.-5:00 p.m.

Salon C Foyer

Registration

PAPER SESSIONS 5-8

8:30 a.m.-10:00 a.m.

Salon F

Paper Session 5: Craving

Session Chairs: Bonnie J. Spring, Ph.D. and Cynthia A. Conklin, Ph.D.

8:30 a.m.

PA5-1

WITHIN-DAY TEMPORAL PATTERNS OF SMOKING IN RELATION TO PATTERNS OF MOOD AND CRAVING

Siddharth Chandra, Ph.D., Deborah Scharf, M.S., Saul Shiffman, Ph.D., University of Pittsburgh*

8:45 a.m.

PA5-2

SMOKING A DE-NICOTINIZED CIGARETTE BLUNTS EMOTIONAL RESPONSE TO POSITIVE MOOD INDUCTION BY PREVIOUSLY DEPRESSED SMOKERS

Bonnie Spring, Ph.D., Anne Maloney, B.S., Bradley Appelhans, Ph.D., Jocelyn Vaughn, B.A., Northwestern University; & Joseph Vanderveen, B.A., Donald Hedeker, Ph.D., University of Illinois Chicago*

9:00 a.m.

PA5-3

DOES SMOKING FOR POSITIVE AND NEGATIVE REINFORCEMENT MODERATE THE RELATIONSHIP BETWEEN AFFECT AND DESIRE TO SMOKE?

Adam. M. Leventhal, M.A., Brown Medical School; Maria P. Archila, Colleen N. Axtell, Elizabeth K. Miller, B.A., Ileana P. Garcia, University of Houston; Christopher W. Kahler, Ph.D., Brown University; & Andrew J. Waters, Ph.D., The University of Texas-M.D. Anderson Cancer Center*

9:15 a.m.

PA5-4

ANGER AND PSYCHOBIOLOGICAL CHANGES DURING SMOKING ABSTINENCE: PREDICTION OF SMOKING RELAPSE

Mustafa al'Absi, Ph.D., Steven B. Carr, B.S., University of Minnesota Medical School, Duluth, Minnesota, Stephan Bongard, Ph.D., Johann Wolfgang Goethe-University, Frankfurt A M., Germany

9:30 a.m.

PA5-5

EXPERIMENTALLY INDUCED ACUTE PAIN ENHANCES SMOKING URGE AND SMOKING BEHAVIOR

Joseph W. Ditre, Melanie N. Jackson, Bill A. Grewe, and Thomas H. Brandon, University of South Florida and the H. Lee Moffitt Cancer Center and Research Institute*

9:45 a.m.

PA5-6

PEOPLE AS CUES TO SMOKE

*C.A. Conklin *, K.A. Perkins, N. Robin, R.P. Salkeld, University of Pittsburgh*



FRIDAY, FEBRUARY 23, 2007

8:30 a.m.-10:00 a.m. Meeting Room 400

Paper Session 6: Pregnancy/Post-Partum

Session Chairs: Raymond Niaura, Ph.D. and Sarah H. Heil, Ph.D.*

8:30 a.m.

PA6-1

VOUCHER-BASED INCENTIVES FOR ABSTINENCE FROM CIGARETTE SMOKING IN PREGNANT AND POSTPARTUM WOMEN

S.H. Heil, S.T. Higgins, L.J. Solomon, M.E. Lynch, L. McHale, A. Dumeer, N. Jacuzzi, L. Shapiro, & I.M. Bernstein, University of Vermont, Burlington, VT*

8:45 a.m.

PA6-2

ACTUAL PRACTICE WHEN EVIDENCE IS UNCLEAR: HOW OFTEN DO PREGNANT SMOKERS USE CESSATION MEDICATIONS AND HOW OFTEN DO OBSTETRIC PROVIDERS RECOMMEND THEM?

Nancy A. Rigotti, M.D., Elyse R. Park, Ph.D., Yuchiao Chang, Ph.D., Susan Regan, Ph.D., Kristin Perry, Tobacco Research & Treatment Center, Massachusetts General Hospital and Harvard Medical School*

9:00 a.m.

PA6-3

EFFECTIVENESS OF ADDING NICOTINE REPLACEMENT THERAPY TO COGNITIVE BEHAVIORAL THERAPY FOR SMOKING CESSATION IN PREGNANT SMOKERS: THE BABY STEPS TRIAL

Kathryn I. Pollak, Ph.D., Cheryl Oncken, M.D.², Isaac M. Lipkus, Ph.D.¹, Bercedis L. Peterson, Ph.D.¹, Geeta K. Swamy, M.D.¹, Pamela K. Pletsch, Ph.D., R.N.³, R. Phillips Heine, M.D.¹, Pauline Lyna, M.P.H.¹, Rebecca J. Namemek Brouwer, M.S.¹, Laura Fish, M.P.H.¹, Evan R. Myers, M.D., M.P.H.¹ ¹Duke University Medical Center; ²University of Connecticut School of Medicine; ³University of Wisconsin*

9:15 a.m.

PA6-4

EFFECTS OF MATERNAL SMOKING DURING PREGNANCY ON INFANT BIRTH WEIGHT DEPEND ON MATERNAL NICOTINE METABOLISM

Laura Stroud, Ph.D., Raymond Niaura, Ph.D., Brown Medical School; Neal Benowitz, M.D., U.C.S.F.; Miriam Lense, B.A., Edmond Shenassa, Sc.D., Lewis Lipsitt, Ph.D., Stephen Buka, Sc.D., Brown Medical School*

9:30 a.m.

PA6-5

THE IMPACT OF MATERNAL SMOKING ON FAST AUDITORY BRAINSTEM RESPONSES AND EARLY LANGUAGE DEVELOPMENT

Julie A. Kable, Claire D. Coles^{1,2}, Mary Ellen Lynch^{1,2} Department of Pediatrics; ²Psychiatry, Emory University School of Medicine, Atlanta, GA, 30306*

9:45 a.m.

PA6-6

TOBACCO USE DURING PREGNANCY: WOMEN'S PERCEPTIONS AND SOCIAL REPRESENTATIONS

Louise Guyon, Quebec National Public Health Institute (QNPPI); Nicole April, M.D., QNPPI; Maria De Koninck, Laval University; Chantale Audet, QNPPI*

8:30 a.m.-10:00 a.m. Salon G

Paper Session 7: Youth Smoking and the Media

Session Chairs: Donna Vallone, Ph.D. and Lois B. Biener, Ph.D.

8:30 a.m.

PA7-1

ASSOCIATION BETWEEN EXPOSURE TO MOVIE SMOKING AND ESTABLISHED ADOLESCENT SMOKING

J. Sargent, M. Stoolmiller, S. Dal Cin, K. Worth, S. Tanski, Dartmouth Medical School; T. Wills, Albert Einstein*

8:45 a.m.

PA7-2

SMOKING IN THE MOVIES: EVIDENCE AND IMPLICATIONS OF IMPACT AMONG YOUNG ADOLESCENTS IN MEXICO

James F. Thrasher, Department of Health Promotion, School of Public Health, University of South Carolina; Edna Arillo-Santillán, Tobacco Research Department, National Institute of Public Health, Mexico; Ana Dorantes, Tobacco Research Department, National Institute of Public Health, Mexico; Eduardo Lazcano-Ponce, Center for Population Health Research, National Institute of Public Health, Mexico. Mauricio Hernández-Ávila, Director, National Institute of Public Health, México*

9:00 a.m.

PA7-3

EFFECT OF MOVIES ON ADOLESCENT SMOKING ONSET MEDIATED THROUGH CHANGES IN EXPECTANCIES AND PEER AFFILIATIONS

**Thomas A. Wills, Ph.D., Albert Einstein College of Medicine; James D. Sargent, M.D., Dartmouth Medical School; Keilah A. Worth, Ph.D., Dartmouth Medical School; Sonya Dal Cin, Ph.D., Dartmouth Medical School. Mike Stoolmiller, Ph.D., University of Oregon; Frederick X. Gibbons, Ph.D., Iowa State University; Susanne E. Tanski, M.D., Dartmouth Medical School*

9:15 a.m.

PA7-4

TELEVISUED MOVIE TRAILERS: UNDERMINING RESTRICTIONS ON ADVERTISING TOBACCO TO YOUTH

Cheryl G. Healtson, Dr.P.H., Ella S. Watson-Stryker, B.A., Jane Appleyard Allen, M.A., Donna M. Vallone, Ph.D., Anna M. Stewart, B.S., M. David Dobbins, Esq., American Legacy Foundation; Peter A. Messeri, Ph.D., Columbia University, Mailman School of Public Health; Stanton A. Glantz, Ph.D., University of California, San Francisco, Center for Tobacco Control Research and Education; Philip R. Graham, M.B.S., Mother, New York*



9:30 a.m.

PA7-5

IMPACT OF TOBACCO-RELATED PRESS COVERAGE ON SMOKING ATTITUDES AND BEHAVIORS OF AMERICAN YOUTH

Melanie Wakefield, Ph.D.*, The Cancer Council Victoria, Australia; Katherine Clegg Smith, Ph.D., Johns Hopkins University; Yvonne Terry-McElrath, M.S.A., Patrick O'Malley, Ph.D., Lloyd Johnston, Ph.D., University of Michigan; Frank Chaloupka, Ph.D., Sherry Emery, Ph.D., University of Illinois at Chicago; and Henry Saffer, Ph.D., Kean University

9:45 a.m.

PA7-6

EXPOSURE TO SMOKING MEDIA AND FRIEND CHOICE IN ADOLESCENCE

William G. Shadel, Ph.D. & Shannah Tharp-Taylor, Ph.D., RAND Corporation

8:30 a.m.-10:00 a.m. Salon C
Paper Session 8: Geographic, Socioeconomic, Racial and Ethnic Factors

Session Chairs: Lisa Sanderson Cox, Ph.D. and Deborah J. Ossip-Klein, Ph.D.

8:30 a.m.

PA8-1

SMOKING TRENDS AMONG FILIPINO ADULTS IN CALIFORNIA, 1990-2005

Romina A. Romero*, M.P.H., Joshua H. West, M.P.H., San Diego State University/University of California, San Diego; Dennis R. Trinidad, Ph.D., M.P.H., Karen Messer, Ph.D., and John P. Pierce, Ph.D., University of California, San Diego

8:45 a.m.

PA8-2

IMPACT OF LIVING WITH A SMOKER ON CESSATION BEHAVIOR: PATTERNS ACROSS DEMOGRAPHIC SUBGROUPS

Laura E. Vichinsky*, Karen A. Davis, M.P.H., M.S.W., Jennifer A. Ellis, Ph.D., Sarah B. Perl, M.P.H., New York City Department of Health and Mental Hygiene

9:00 a.m.

PA8-3

ETHNIC DISPARITIES IN SMOKING CESSATION AND TOBACCO TREATMENT AMONG MIDDLE-AGED SMOKERS

Steven S. Fu, M.D., MSCE*, Molly Kodl, Ph.D., Anne M. Joseph, M.D., M.P.H., Minneapolis VA Medical Center and University of Minnesota; Dorothy K. Hatsukami, Ph.D., University of Minnesota; Eric O. Johnson, Ph.D., Research Triangle Institute International; Naomi Breslau, Ph.D., Michigan State University; Baolin Wu, Ph.D., University of Minnesota; Laura Bierut, Ph.D., Washington University, St. Louis

9:15 a.m.

PA8-4

REGIONAL DIFFERENCES IN SMOKING BEHAVIOR: TAILORING OUR EFFORTS

Victor J.C.*, Diemert L.M., Bondy S., Brown K.S., Cohen J., Ferrence R., Garcia J., McDonald P., Selby P., Stephens T. ¹Ontario Tobacco Research Unit; ²University of Toronto; ³University of Waterloo; ⁴Centre For Addiction and Mental Health

9:30 a.m.

PA8-5

TAILORING EVIDENCE-BASED TOBACCO CONTROL INTERVENTIONS TO LOW-MIDDLE INCOME COUNTRIES: A CASE EXAMPLE FROM THE DOMINICAN REPUBLIC

D.J. Ossip-Klein*, S. Díaz, A. Dozier, Z. Quiñones, E. Sierra, Z. Castillo, J. Guido, S. McIntosh, O. Díaz, S. Fisher, N. Chin, University of Rochester Medical Center

9:45 a.m.

PA8-6

IMPACT AND PERCEPTIONS OF WARNING LABELS ACROSS SEVEN COUNTRIES: FINDINGS FROM THE INTERNATIONAL TOBACCO CONTROL POLICY EVALUATION PROJECT

Maizurah Omar*, Ph.D., Foong Kin, Ph.D., Rahmat Awang, Ph.D., National Poison Center, Universiti Sains Malaysia; Geoffrey T. Fong, Ph.D., David Hammond, Ph.D., University of Waterloo, Buppha Sirirassamee, Ph.D., Institute for Population and Social Research, Mahidol University; Pete Driezen, M.Sc., University of Waterloo

10:00 a.m.-10:30 a.m. Salon J/K Foyer
Refreshment Break

10:30 a.m.-11:30 a.m. Salon C
Pre-Clinical Theme Lecture: Anthony R. Caggiula, Ph.D.

"What is the Role of Nicotine in Smoking? A Perspective from Animal Research"

Introduction by William Corrigan, Ph.D.

11:00 a.m.-5:00 p.m. Salon H
Exhibit Hall Open

11:30 a.m.-1:30 p.m. Salon H-Exhibit Hall
Poster Session II

Lunch - Boxed Lunches Served in Salon H-Exhibit Hall
(Exchange Your Lunch Ticket for Boxed Lunch)



FRIDAY, FEBRUARY 23, 2007

SYMPOSIUM SESSIONS 5-8

1:30 p.m.-3:00 p.m. Salon G Symposium 5

FACTORS THAT IMPACT NICOTINE BIOAVAILABILITY: FINDINGS FROM THE TRANSDISCIPLINARY TOBACCO USE RESEARCH CENTERS PROGRAM

Nicotine is the major pharmacologically active alkaloid in tobacco and the main reason why many tobacco users struggle to quit. Nicotine creates dependence by activating the dopaminergic reward system in the brain. Physiologic withdrawal symptoms that occur when nicotine is no longer administered reinforce continued nicotine administration to avoid withdrawal. Extrapolating from this evidence has led to the development of tobacco dependence pharmacotherapy based upon the concept of replacing and/or blocking the effects of nicotine in the brain. Evidence also suggests that contemporary tobacco products are carefully engineered to deliver finely graded doses of nicotine to the tobacco user addicted. While the central role of nicotine in tobacco use behavior is well accepted what remains unknown is why there is such wide variation in how tobacco users respond to different tobacco products and stop medications. This symposium includes four papers from the NIH supported Transdisciplinary Tobacco Use Research Centers Program and their collaborators that examine various factors help explain individual variation in nicotine bioavailability. The four papers included in this session will provide insight about how agent (i.e., cigarette design, stop smoking medications) and host (genetic and demographic) factors interact to influence the bioavailability of nicotine and impact smoking behavior and response to pharmacologic treatments for nicotine dependence. The paper by Rachel Tyndale will explore the role of genetic variation in nicotine metabolizing enzymes (CYP2A6 and CYP2B6) on bioavailability of nicotine and smoking cessation treatment outcomes. The paper by Sharon Murphy will present data on the role of glucuronidation in nicotine metabolism. Cliff Watson will present data from the CDC's laboratory effort to measure free nicotine levels in popular cigarette brands. Finally, Dave Hammond will present the results of a study comparing different cigarette machine testing regimens in terms of their ability to predict cotinine levels measured in adult smokers. Neal Benowitz, will serve as a discussant to the session.

Presenters: Rachel F. Tyndale, Ph.D., University of Toronto (Canada); Sharon Murphy, Ph.D., University of Minnesota (USA); Cliff Watson, Ph.D., Centers for Disease Control and Prevention (USA); David Hammond, Ph.D., University of Waterloo, (Canada); Discussant: Neal Benowitz, M.D., University of California, San Francisco (USA); Organizer: K. Michael Cummings, Ph.D., M.P.H., Roswell Park Cancer Institute (USA)*

1:30 p.m.-3:00 p.m. Salon F Symposium 6

EXPANSION OF NON-CIGARETTE TOBACCO PRODUCTS: CURRENT RESEARCH AND POLICY IMPLICATIONS

The goal of this symposium is to focus scientific and policy attention on non-cigarette tobacco products. This symposium will present research (e.g., prevalence, toxicity/biomarker data, consumer risk perceptions) on various non-cigarette tobacco products, including cigars, smokeless tobacco (SLT) and waterpipes, and the panel will discuss the policy implications stemming from this data as well as identifying key research questions requiring further study that will better inform policy makers', consumers' and treatment professional's responses to non-cigarette tobacco products. Mr. Barry will provide an overview of the key research and policy issues raised by the use of non-cigarette tobacco products, whether the research and policy communities have neglected non-cigarette tobacco products relative to cigarettes, and why these products warrant the attention of scientists and policymakers. Dr. Delnevo will present data on cigar prevalence in the U.S., including little and flavored cigars, and how these products are competing with cigarettes for market share. Dr. Eissenberg will present prevalence and toxicity/biomarker data on waterpipes, including consumer misperceptions of risk associated with waterpipe use. Dr. Hatsukami will present toxicity/biomarker data on SLT, particularly low-nitrosamine SLT, and discuss how these products are viewed in the broader "harm reduction" debate. Ms. Kemper will present focus group data on smoker/consumer perceptions of new SLT products (Camel Snus, Taboka) and the impact of these products and how they are marketed on interest in switching from cigarettes to SLT and on quitting tobacco use. Mr. Mitch Zeller will serve as the discussant to the panel.

Presenters: Matthew Barry, M.P.A., Campaign for Tobacco Free Kids; Cristine Delnevo, Ph.D., M.P.H., UMDNJ-School of Public Health; Thomas Eissenberg, Ph.D., Virginia Commonwealth University; Dorothy K. Hatsukami, Ph.D., University of Minnesota; Katherine E. Kemper, GlaxoSmithKline.*

1:30 p.m.-3:00 p.m. Meeting Room 400 Symposium 7—Presidential Symposium

USING SOCIAL MARKETING TO INFLUENCE TOBACCO USE BEHAVIOR: THE EXPERIENCE OF THE AMERICAN LEGACY FOUNDATION

The American Legacy Foundation uses social marketing to prevent youth smoking, increase adult cessation and encourage families to adopt home smoking bans. This symposium will highlight five Legacy campaigns and three campaigns that were funded through Legacy's grants program. Each of these examples illustrates how Legacy uses social marketing to achieve its public health goals. This symposium should be of interest to anyone who is interested in using social marketing - whether at the national or local level—to influence smoking or tobacco use behavior. The symposium will conclude by describing how Lorillard Tobacco Company attempted to shut down Legacy based on the claim that the edgy truth campaign "vilified" and "personally attacked" the corporation. The tobacco control community will be interested in learning what can happen when an effective social marketing campaign draws the attention of the tobacco industry.

FRIDAY, FEBRUARY 23 - SATURDAY, FEBRUARY 24, 2007



Presenters: Cheryl G. Heaton, Dr.P.H., Donna Vallone, Ph.D., Joseph Martyak, J.D., Amber Thornton, M.P.H., C.H.E.S., Jane A. Allen, M.A., Ellen Vargyas, J.D., Jennifer Duke, Ph.D., American Legacy Foundation. Ellen R. Gritz, Ph.D., M.D. Anderson Cancer Center (discussant)*

1:30 p.m.-3:00 p.m. Salon C Symposium 8

ADDRESSING COMORBID PSYCHIATRIC PROBLEMS IN THE TREATMENT OF NICOTINE DEPENDENCE

Associations between cigarette smoking and psychiatric disorders have been well established over the past several decades. Smokers have higher rates of psychiatric comorbidity than non-smokers, and disproportionately higher rates of cigarette smoking have been observed among psychiatric populations. Research also indicates that having a psychiatric disorder or current psychiatric symptoms conveys a greater risk for smoking cessation failure. New research findings are needed to guide nicotine dependence treatment efforts for smokers with psychiatric problems. This symposium offers transdisciplinary research from four distinct comorbid psychiatric problem areas (alcohol, PTSD, schizophrenia and depression). Presentations will focus on behavioral treatments, pharmacotherapy and mechanisms of action in these at-risk populations of smokers. Dr. Kahler's presentation will focus on smokers who are heavy drinkers, and will present outcome data from a randomized clinical trial (RCT) evaluating the efficacy of an innovative brief alcohol intervention combined with transdermal nicotine patch (TNP). Dr. Beckham's presentation will focus on smokers with post-traumatic stress disorder (PTSD), and will feature electronic diary data examining affective antecedents and consequences of smoking in PTSD vs. non-PTSD smokers. Dr. George's presentation offers encouraging findings from a placebo controlled RCT examining the incremental efficacy of bupropion when added to TNP in smokers with schizophrenia or schizoaffective disorder. Finally, Dr. Brown's presentation will focus on smokers with elevated depressive symptoms, providing evidence from a novel RCT evaluating the timing of fluoxetine administration. Findings suggest that treating depressive symptoms sequentially (prior to brief behavioral cessation treatment with TNP) is superior to the more common, concurrent treatment of depressive symptoms. Dr. John Hughes will serve as discussant for the session and will synthesize across disciplines and presentations, and will highlight implications for future research in this area.

Presenters: Richard A. Brown, Ph.D., Christopher W. Kahler, Ph.D., Brown Medical School, Tony P. George, M.D., University of Toronto, Jean C. Beckham, Ph.D., Duke University Medical Center, John Hughes, M.D., University of Vermont*

3:00 p.m.-3:30 p.m. Salon H – Exhibit Hall Refreshment Break

3:30 p.m.-4:30 p.m. Salon C Epidemiology/Public Health Theme Lecture: Ron Borland, Ph.D.

"Integrating Tobacco Industry and Tobacco Use Control: Tackling Harm and Dependence in a Culture of Consumption"

Introduction by Harry Lando, Ph.D.

4:30 p.m.-5:30 p.m. Salon C Members' Meeting

Ellen Gritz, Ph.D., President of SRNT

SATURDAY, FEBRUARY 24, 2007

7:00 a.m.-3:00 p.m. Meeting Room 602 Cyber Café

7:30 a.m.-2:30 p.m. Salon C Foyer Registration

SYMPOSIUM SESSIONS 9-12

8:00 a.m.-9:30 a.m. Meeting Room 400 Symposium 9

HUMAN ALLELIC VARIATION THAT CONTRIBUTES TO NICOTINE DEPENDENCE AND SUCCESS IN SMOKING CESSATION

Classical genetic studies now unequivocally indicate that about half of human individual differences in vulnerability to nicotine dependence comes from genetics. These influences on vulnerability to nicotine dependence overlap substantially with genetic influences on vulnerability to dependence on other substances. Interestingly, replicated studies also find that about half of the ability to quit smoking is also genetic. Linkage, association genome scanning ("whole genome association") and candidate gene studies now provide a substantial body of information about the molecular genetic influences on addiction vulnerability. The molecular genetic vulnerability for nicotine dependence appears to be polygenic; no single gene provides a very large influence. The molecular genetic vulnerability for nicotine dependence overlaps with vulnerabilities to dependence on other addictive substances, as indicated by the classical genetic studies. The molecular genetic bases of successful nicotine cessation appear to overlap partially, but not completely, with the genetic bases of vulnerability to nicotine dependence. Gene variants that contribute to individual differences in vulnerability to nicotine dependence and ability to successfully stop smoking identify a number of genes that might not have been anticipated, including those that encode molecules related to "cell adhesion" processes, enzymes and transcription factors as well as receptors and transporters. Taken together, these findings provide novel insights into the molecular bases of nicotine dependence and the ability to successfully quit smoking. Information about the allelic variants that contribute to success in smoking cessation provide information that we can use to model effects of stratification by genotypes on the cost and power of clinical trials for smoking cessation. As trial costs increase and genotyping costs



decline, even markers that detect 1/2 of the total genetic contributions to smoking cessation success can make a large impact in reducing trial costs and enhancing trial power.

Presenters: G. Swan, SRI International, C. Lerman, University of Pennsylvania; L. Beirut, Washington University, St Louis, G. Uhl, NIH; Jed Rose, Discussant

**8:00 a.m.-9:30 a.m. Salon G
Symposium 10**

MOLECULES TO BEHAVIOR: THE INFLUENCE OF GENDER AND HORMONES ON RESPONSES TO NICOTINE AND SMOKING CESSATION

Women are less likely than men to quit smoking successfully, although the reasons underlying this phenomenon are not well understood. Potential factors include differences in response to nicotine, severity of dependence, sensitivity to conditioned cues and the nature of withdrawal, which in turn could be linked to differences in sex steroids or molecular mechanisms involving brain nicotinic receptor levels. Using data from two smoking cessation studies, Dr. Piper will present findings on gender differences in tobacco dependence and withdrawal responses using ecological momentary assessment. Dr. Allen will examine menstrual cycle modulation of factors that may contribute to smoking relapse in women randomized to quit during either the follicular phase or the luteal phase, phases that differ in levels of ovarian hormones, including progesterone and estrogen. Using a laboratory paradigm, Dr. Sofuoglu will present data on sex differences in response to IV nicotine and the modulation of these responses by progesterone in male and female smokers. At the molecular level, Dr. Staley will present neuroreceptor imaging data suggesting that women have higher levels of brain nicotinic receptors and that these levels are not regulated by fluctuating ovarian hormones. Dr. Hatsukami will discuss how these findings, derived from studies that span molecular to clinical research, advance our understanding of how sex differences influence nicotine dependence and smoking cessation.

Presenters: Stephanie S. O'Malley, Ph.D., Carolyn M. Mazure, Ph.D., Mehmet Sofuoglu, M.D., Ph.D., Julie Staley, Ph.D., Yale University School of Medicine; Megan E. Piper, Ph.D., University of Wisconsin; Sharon Allen, M.D., Ph.D., Dorthy Hatsukami, Ph.D., University of Minnesota.*

**8:00 a.m.-9:30 a.m. Salon C
Symposium 11**

CUE-PROVOKED CRAVING: OBSERVATIONS, MECHANISMS, AND CLINICAL IMPLICATIONS

Smokers experience bursts of intense craving when they encounter cues that are associated with smoking. These episodic peaks in craving seem distinct from the general background level of craving smokers may experience during ad lib smoking or during abstinence. Such "cue reactivity" and "provoked craving" is particularly prominent when smokers quit, and research shows that these episodic cravings may be responsible for most relapse. This symposium discusses cue reactivity from multiple perspectives. Saul Shiffman reviews field data in clinical samples, showing that relapse episodes typically occur in the context of cravings provoked by exposure to stimuli such as seeing or smelling smoking, drinking alcohol or coffee, or experiencing

negative affect. These data also show that, even smoking in the face of such cues, can be prevented through acute intervention. Michael Sayette reviews methods and findings using the laboratory cue-reactivity paradigm, which models these experiences under controlled laboratory conditions. Among the findings are that smokers who react more strongly to cue exposure are more likely to relapse, and that responses to cues differs depending on the perceived expectancy of smoking. Joseph McClernon reviews recent brain-imaging studies showing that exposure to smoking cues elicits distinctive patterns of brain activation, which correlate with subjectively-reported craving. The studies show that cue-induced craving leads to patterns of brain activation distinct from those seen during deprivation-induced craving, suggesting different mechanisms for the two types of craving. Finally, Ray Niaura will discuss the implications of provoked craving for understanding smoking, smoking cessation, and relapse, touching on the role of conditioning in provoked craving and on the potential for behavioral and pharmacological interventions to target provoked craving responses.

Presenters: Saul Shiffman, Ph.D., University of Pittsburgh, Pittsburgh, PA; Michael Sayette, Ph.D., University of Pittsburgh, Pittsburgh, PA; F. Joseph McClernon, Ph.D., Duke University Medical Center, Durham, NC; Raymond Niaura, Ph.D., Brown Medical School, Providence, RI*

**8:00 a.m.-9:30 a.m. Salon F
Symposium 12**

PARENT SMOKING, PARENTING, AND ADOLESCENT SMOKING: MODERATORS, MEDIATORS, AND RECIPROCAL INFLUENCES

The relationship between parent smoking and adolescent smoking is well established. More recent data have shown that general parenting practices (e.g., monitoring) and antismoking parenting (e.g., communicating with adolescents about smoking) might prevent adolescent smoking initiation and escalation. However, we do not understand how these parent factors and adolescent smoking fit together in meaningful ways. Specifically, we do not know the possible moderators, mediators, and reciprocal influences in the relationship between parent smoking, parenting, and adolescent smoking. Such knowledge can help lead to the development of innovative theory-based family-focused interventions that might prevent adolescent smoking. This symposium will help fill this knowledge gap with presentations of three theory-based longitudinal studies utilizing parent and adolescent data from cohorts in the US and the Netherlands. Jonathan Bricker will present data showing the personality traits (for example, thrill seeking) that significantly enhanced the influence of parent smoking on adolescent smoking transitions. Zeena Harakeh will present the findings that the following antismoking parenting behaviors were each significant mediators of parent smoking: 1) perceived influence of parents on adolescent smoking; and, 2) quality of parent-adolescent communication on smoking-related topics. Molly Kodl will show that both general and antismoking parenting prevented adolescent smoking escalation whereas there was little evidence that adolescent smoking escalation was associated with changes in parenting. Her presentation will also show that parent smoking and antismoking parenting had independent mechanisms of influence on adolescent smoking. Finally, Denise Kandel will discuss the above



papers, which will include insights on their implications for theory and the development of family-based interventions for adolescent smoking prevention.

Presenters: Jonathan B. Bricker, Ph.D., Fred Hutchinson Cancer Research Center; Zeena Harakeh, Ph.D.*, Radboud University Nijmegen; Molly M. Kodl, Ph.D., Minneapolis Veterans' Affairs Medical Center; Denise B. Kandel, Ph.D.*, Columbia University*

9:30 a.m.-10:00 a.m. Salon J/K Foyer
Refreshment Break

PAPER SESSIONS 9-12

10:00 a.m.-11:30 a.m. Salon G
Paper Session 9: Biological Variation

Session Chairs: David G. Gilbert, Ph.D. and Laurie A. Zawertailo, Ph.D.

10:00 a.m.

PA9-1

THE SHORT END OF THE SEROTONIN TRANSPORTER STICK STRIKES AGAIN: EFFECTS OF SERT GENOTYPE ON SMOKING ABSTINENCE SYMPTOMS

David G. Gilbert, Ph.D., Yantao Zuo, Ph.D., Norka E. Rabinovich, B.A., Rachel Needham, & Jodi I. Huggenvik, Ph.D., Southern Illinois University at Carbondale

10:15 a.m.

PA9-2

THE DRD2 TAQ1 POLYMORPHISM INTERACTS WITH GENDER AND SMOKING DEPRIVATION IN PREDICTING SELF-REPORTED WITHDRAWAL

**David E. Evans, Ph.D., Liliana Huaman, B.S., Sang-Hak Lee, M.D., Jong Park, Ph.D., & David J. Drobes, Ph.D., H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, Florida*

10:30 a.m.

PA9-3

GENETIC VULNERABILITY TO DSM-IV NICOTINE WITHDRAWAL: AUSTRALIAN AND FINNISH FAMILIES

*Michele L. Pergadia^{*1}, Arpana Agrawal¹, Anu Loukola^{2,3}, Grant W. Montgomery⁶, Ulla Broms⁴, Scott F. Saccone¹, Andrew C. Heath¹, Danielle M. Dick¹, Alexandre A. Todorov¹, Heidi Maunu^{2,4}, Kauko Heikkilä⁴, Katherine I. Morley⁵, John P. Rice¹, Richard D. Todd¹, Jaakko Kaprio^{4,6}, Leena Peltonen², Nicholas G. Martin⁵, Alison M. Goate¹, Pamela A.F. Madden¹ ¹Department of Psychiatry, Washington University School of Medicine, Saint Louis, USA; ²Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland; ³Finnish Genome Center, University of Helsinki, Helsinki, Finland; ⁴Department of Public Health, University of Helsinki, Helsinki, Finland; ⁵Queensland Institute of Medical Research, Brisbane, Australia; ⁶Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland*

10:45 a.m.

PA9-4

POLYMORPHISMS IN THE DOPAMINE TRANSPORTER GENE (DAT1): INFLUENCES ON COGNITION, BEHAVIOUR AND RISK OF RELAPSE

**Lynne E Dawkins, University of East London, UK; Nuria Mellado Calvo, Institute of Psychiatry, London, UK; John Powell, Institute of Psychiatry, London, UK; Jane H Powell, Goldsmiths College, London, UK; Alan Pickering, Goldsmiths College, London, UK; Robert West, University College London, UK*

11:00 a.m.

PA9-5

CLINICAL AND GENETIC CHARACTERIZATION OF CO-MORBID TOBACCO DEPENDENCE AND PATHOLOGICAL GAMBLING

Laurie Zawertailo, Ph.D., Shazia Syed, Daniela Lobo, M.D., James Kennedy, M.D., Usoa Busto, Pharm.D. Neuroscience Research Department, Centre for Addiction and Mental Health*

11:15 a.m.

PA9-6

PHARMACOLOGICAL MRI OF SMOKED TOBACCO

Kimberly P. Lindsey, Ph.D., Elizabeth T. Ryan, M.A., Scott E. Lukas, Ph.D., Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Belmont, M.A.; Lisa D. Nickerson, Ph.D., Blaise deB. Frederick, Ph.D. Brain Imaging Center, McLean Hospital, Belmont, MA

10:00 a.m.-11:30 a.m. Meeting Room 400
Paper Session 10: Attention

Session Chairs: Thomas J. Gould, Ph.D. and Alexandra S. Potter, Ph.D.

10:00 a.m.

PA10-1

THE EFFECTS OF SMOKING-RELATED STIMULI ON COGNITIVE PERFORMANCE

Betha Kleykamp, M.A., Janine Jennings, Ph.D., Cynthia Sams, R.N., Dena Shaffer, B.S., Janet Austin, M.S., Jennifer Gray, B.S., Michael Weaver, M.D., and Thomas Eissenberg, Ph.D., Virginia Commonwealth University and Wake Forest University*

10:15 a.m.

PA10-2

SELECTIVE ATTENTION OF SMOKERS AND NONSMOKERS AS MEASURED BY THE D2 TEST OF ATTENTION

*Allen Azizian^{*1}, John R. Monterosso¹, Sara L. Simon¹, Arthur L. Brody¹, and Edythe D. London^{1,2,3}; ¹Department of Psychiatry and Biobehavioral Sciences; ²Department of Molecular and Medical Pharmacology, David Geffen School of Medicine; and ³The Brain Research Institute, University of California Los Angeles, Los Angeles, CA*



SATURDAY, FEBRUARY 24, 2007

10:30 a.m.

PA10-3

ATTENTIONAL MECHANISMS AND THEIR ASSOCIATIONS WITH NICOTINE DEPENDENCE AND SUCCESS DURING A QUIT ATTEMPT

*Sandra J. Japuntich^{*1,2}, Rebecca Gloria¹, Timothy B. Baker^{1,2}, John J. Curtin¹; ¹Psychology Department, University of Wisconsin-Madison; ²Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health*

10:45 a.m.

PA10-4

ATOMOXETINE AND BUPROPION AMELIORATE NICOTINE WITHDRAWAL-ASSOCIATED DEFICITS IN CONTEXTUAL LEARNING: INVESTIGATION OF THE NEURAL SUBSTRATES OF NICOTINE WITHDRAWAL

Thomas J Gould, Ph.D. Department of Psychology, Temple University Philadelphia, PA 19122*

11:00 a.m.

PA10-5

EFFECTS OF ACUTE NICOTINE ON MOTOR PERFORMANCE IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

A.S. Potter, P.A. Newhouse Clinical Neuroscience Research Unit, Dept. of Psychiatry, University of Vermont College of Medicine, Burlington, VT 05401*

11:15 a.m.

PA10-6

SAFETY AND FEASIBILITY OF ATOMOXETINE FOR SMOKING CESSATION IN YOUNG SMOKERS WITH AND WITHOUT ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD): A PILOT STUDY

Himanshu Upadhyaya, M.B.B.S., M.S., Kevin Gray, M.D., Matthew Carpenter, Ph.D., Annie Simpson, M.Sc., & Gina Frattaroli, B.A. Medical University of South Carolina*

**10:00 a.m.-11:30 a.m. Salon F
Paper Session 11: New Medications**

Session Chairs: Nancy A. Rigotti, M.D. and Susan H. Swartz, M.D., M.P.H.

10:00 a.m.

PA11-1

THE EFFECT OF NICOTINE DEPENDENCE LEVEL ON QUIT OUTCOMES WITH VARENICLINE: RESULTS FROM A POOLED-ANALYSIS OF CONTROLLED TRIALS

Dr. Susan Swartz, Maine Medical Center, Portland, ME, USA; Dr. David Gonzales, OHSU Smoking Cessation Center, Oregon Health & Science University, Portland, OR, USA; Clare B. Billing, Jr., Eric Watsky, Jason Gong, Kathryn Williams, Karen Reeves, Pfizer Global Research and Development, Groton/New London, CT, USA*

10:15 a.m.

PA11-2

QUITTING PATTERNS DURING 12 WEEKS OF TREATMENT FOR SMOKING CESSATION WITH VARENICLINE: RESULTS FROM A POOLED-ANALYSIS OF VARENICLINE VS BUPROPION OR PLACEBO

David Gonzales, OHSU Smoking Cessation Center, Oregon Health & Science University, Portland, OR, USA; Susan Swartz, Maine Medical Center, Portland, ME, USA; Cheryl Oncken, University of Connecticut School of Medicine, Farmington, CT, USA; Hao Wang, Pfizer, Inc; New York, NY, USA; Karen Reeves, Jason Gong, Eric Watsky, Kathryn Williams, Pfizer Global Research and Development, Groton/New London, CT, USA*

10:30 a.m.

PA11-3

EFFECT OF VARENICLINE ON CUE-PROVOKED CIGARETTE CRAVING AND ACUTE NICOTINE WITHDRAWAL

Raymond Niaura, Ph.D., Brian Hitsman, Ph.D., William G. Shadel, Ph.D., Dana M. Britt, Ph.D., & Lawrence H. Price, M.D. Brown Medical School, Providence, Rhode Island*

10:45 a.m.

PA11-4

EFFICACY AND SAFETY OF ADDING A NICOTINE PATCH TO RIMONABANT FOR SMOKING CESSATION: A RANDOMIZED CONTROLLED TRIAL

Nancy A. Rigotti, M.D., Massachusetts General Hospital & Harvard Medical School; David Gonzales, Ph.D., Oregon Health & Science University; Lowell C. Dale, M.D., Mayo Medical School; Daniel Lawrence, Ph.D., University of Wisconsin Medical School; for the CIRRU Study Group*

11:00 a.m.

PA11-5

ALCOHOL HISTORY AND SMOKING CESSATION IN NICOTINE REPLACEMENT THERAPY, BUPROPION AND VARENICLINE TRIALS: A REVIEW

Robert F. Leeman, Yale University School of Medicine; Christopher J. Huffman, University of South Carolina School of Medicine. Stephanie S. O'Malley, Yale University School of Medicine*

11:15 a.m.

PA11-6

EFFECTIVENESS OF SMOKING CESSATION THERAPIES: A SYSTEMATIC REVIEW AND META-ANALYSIS

*Edward J. Mills, M.Sc., Ph.D.*¹, Ping Wu, M.B.B.S, M.Sc.¹ Popey Dimoulas-Graham, M.Sc.² Kumanan Wilson, M.D., M.Sc.³; ¹Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada. ²Department of Public Health, York Regional Health System, York Region, Canada; ³Department of Medicine, University of Toronto, Toronto, Canada*



10:00 a.m.-11:30 a.m. Salon C
Paper Session 12: Predictors of Change in Smoking

Session Chairs: Lisa C. Dierker, Ph.D. and Joan S. Tucker, Ph.D.

10:00 a.m.

PA12-1

PSYCHOSOCIAL PREDICTORS OF SMOKING TRAJECTORIES FROM ADOLESCENCE TO YOUNG ADULTHOOD

Lisa C. Dierker, Darcé Costello, Wesleyan University*

10:15 a.m.

PA12-2

SMOKING INITIATION IN YOUNG ADULTHOOD: HOW LATE INITIATORS DIFFER FROM EARLY INITIATORS

Kelli-an Lawrance Ph.D., Brock University, 500 Glenridge Ave, St. Catharines, ON, L2S 3A1, Canada; Aoife Gavin B.A., Brock University, 500 Glenridge Ave, St. Catharines, ON L2S 3A1, Canada; Linda Jessup Ph.D., University of Waterloo, 200 University Ave West, Waterloo, ON, N2L 3G1, Canada*

10:30 a.m.

PA12-3

TEMPORAL ASSOCIATIONS OF CIGARETTE SMOKING WITH SOCIAL INFLUENCES, ACADEMIC PERFORMANCE, AND DELINQUENCY: A FOUR-WAVE LONGITUDINAL STUDY FROM AGE 13 TO 23

Joan S. Tucker, Ph.D., Felipe Martinez, Ph.D., Phyllis L. Ellickson, Ph.D., Maria Orlando Edelen, Ph.D., RAND Corporation*

10:45 a.m.

PA12-4

DOES PERSONALITY MODIFY THE INFLUENCE OF CLOSE FRIENDS' SMOKING ON ADOLESCENTS' SMOKING TRANSITIONS?: A LONGITUDINAL STUDY

Jonathan B. Bricker, Ph.D., M. Robyn Andersen, Ph.D., K. Bharat Rajan, M.S., Irwin G. Sarason, Ph.D., Madelaine Ramey, Ph.D., Brian G. Leroux, Ph.D., Arthur V. Peterson, Jr., Ph.D., Fred Hutchinson Cancer Research Center*

11:00 a.m.

PA12-5

EFFECTS OF INATTENTIVE AND HYPERACTIVE-IMPULSIVE SYMPTOMS ON DEVELOPMENT OF NICOTINE DEPENDENCE FROM MID ADOLESCENCE TO YOUNG ADULTHOOD

Daniel Rodriguez, Ph.D., Department of Psychiatry, University of Pennsylvania, Kenneth P. Tercyak, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, & Janet Audrain-McGovern, Department of Psychiatry, University of Pennsylvania*

11:15 a.m.

PA12-6

CIGARETTE SMOKING AND ALCOHOL USE AS PREDICTORS OF MARIJUANA USE IN ADOLESCENCE AND YOUNG ADULTHOOD

Steffani R. Bailey, Ph.D., Stanford Prevention Research Center; Stephen T. Tiffany, Ph.D., University of Utah School of Medicine; Michelle L. Rogers, Ph.D., Brown University*

11:30 a.m.-1:30 p.m. Salon H

Poster Session 3 – Rapid Response Posters

Box Lunch Provided

(Exchange Your Lunch Ticket for a Boxed Lunch)

1:30 p.m.-2:00 p.m. Salon C

Closing Remarks

Ellen Gritz, Ph.D., SRNT President, 2006-2007; Incoming President, Raymond Niaura, Ph.D.; 2007 SRNT Program Chair, Eric Donny, Ph.D.; 2008 SRNT Program Co-Chair, Robbie Schnoll, Ph.D.